Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

G1 Therapeutics Inc.

www.g1therapeutics.com

Latest From G1 Therapeutics Inc.

Tecentriq Takes EU Lead In Triple-Negative Breast Cancer

Roche’s checkpoint inhibitor has been approved in combination with nab-paclitaxel in the EU for triple-negative breast cancer, cementing the company’s role as an innovator in breast cancer therapies.

 

ImmunoOncology Approvals

Finance Watch: Hatteras Nearly Halfway To $200m Goal For New Early-Stage VC Fund

Private Company Edition: General Partner Clay Thorp says the venture capital firm's longtime focus on seed and early-stage investments is unchanged and bolstered by market fundamentals. Also, Talaris and insitro each raised $100m Series A rounds, plus other financings.

Financing StartUps and SMEs

NCI Director And Former Dx Start-Up Founder Sharpless Will Helm FDA

After a week of speculation as to who will succeed US FDA Commissioner Scott Gottlieb when he steps down next month, Health and Human Services Secretary Alex Azar announced during a congressional hearing that National Cancer Institute Director Ned Sharpless will step in as acting commissioner. One note of medtech interest in Sharpless' bio: he was a co-founder of a diagnostics company.

Regulation FDA

Finance Watch: Lilly Completes Elanco Animal Health Spin-Out As New IPO Filings Keep Rising

Public Company Edition: Eli Lilly & Co. wasted no time spinning out its animal health business Elanco, which raised $1.5bn in its public debut. Also, as the biopharma IPO tally rises, Vivo Capital launches a new public life science company fund. Meanwhile, Concordia completes its recapitalization.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • G-Zero Therapeutics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • G1 Therapeutics Inc.
  • Senior Management
  • Mark A Velleca, MD, PhD, CEO
    Barclay A Phillips, SVP, Corp. Dev. & CFO
    Jay C Strum, PhD, CSO
    Raj Malik, MD, SVP, R&D & CMO
    Mark Avagliano, CBO
  • Contact Info
  • G1 Therapeutics Inc.
    Phone: (919) 213-9835
    4501 Research Commons, 79 TW Alexander
    Ste. 100
    Research Triangle Park, NC 27709
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register